4McLEAN MJ. Clinical pharmacokinetics of gabapentin[J]. Neurology, 1994 ,44 Suppl 5: S17-S22.
5McLEAN MJ, MORRELL MJ, WILLMORE LJ, et al. Safety and tolerability of gabapen tin as adjunctive therapy in a large, multicenter study[J]. Epilepsia, 1999, 4 0(7): 965-972.
6GIDAL BE, deCERCE J, BOCKBRADER HN, et al. Gabapentin bioavailability : effect of dose and frequency of administration in adult patients with epilepsy[J]. Epilepsy Res, 1998, 31(2): 91-99.
7BEYDOUN A, FAKHOURY T, NASREDDINE W, et al. Conversion to high dose g abapent in monotherapy in patients with medically refractory partial epilepsy[J]. Epil epsia, 1998, 39(2): 188-193.
8WILSON EA, SILLS GJ, FORREST G, et al. High dose gabapentin in refract ory par tial epilepsy: clinical observations in 50 patients[J]. Epilepsy Res, 1998, 2 9(2): 161-166.
9BERAN R, BERKOVIC S, BLACK A, et al. Australian study of titration to effect profile of safety (AUS-STEPS): high-dose gabapentin(neurontin) in partial seiz ures[J]. Epilepsia, 2001, 42(10): 1335-1339.
10BAO KR. Epilepsy and drugs therapy[J].New Drugs Clin Rem(in Chin ese), 1997, 16(5):286-288.
